Table 3.

Treatment outcomes by STK pathways for STK inhibitors only (clinical trial cohort).

		mTOR/AKT/PI3K pathway				Aurora pathway	MAPK/MEK/Raf pathway
	All STK inhibitors	All pathways	mTOR	AKT	PI3K	All pathways	All pathways	Sorafenib
Response rates (RECIST)
No. of subjects (n)	299a	74	54	0	20	82	163	76
Response rate (%)	10	18	9	n/a	40	6	12	5
Clinical benefit rateb (%)	64	95	n/a	n/a	95	69	63	47
Complete response (%)	1	1	0	n/a	5	0	1	0
Partial responseb (%)	9	16	9	n/a	35	6	11	5
Stable diseaseb (%)	53	55	n/a	n/a	55	61	50	42
Progressive disease	35	5	n/a	n/a	5	29	37	53
Response rates (CA125)
No. of subjects (n)	98	0	0	0	0	51	47	0
Response rates (%)	16	n/a	n/a	n/a	n/a	20	13	n/a
Survival time (months)c
PFS	2.7	5.1	3.1	n/a	7.0	2.0	5.6	2.1
OS	14.1	11.6	11.6	n/a	n/a	9.8	16.3	16.3

Response rate includes complete response and partial response. Clinical benefit rate includes complete response, partial response, and stable disease.

^aNot all subjects included in Table 2 were evaluable for treatment response so numbers differ.

^bTwo trials (87 subjects) did not include data on rates of stable disease and progressive disease, so these subjects were removed from analysis of clinical benefit rate, stable disease, and progressive disease (for study with mTOR pathway inhibitor with temsirolims, subgroup of the study showed at least 53% of clinical benefit rate based on 51 cases reporting treatment response).

^cSurvival time is described from study enrollment to final status, numbers are described as median of median reported in each study (not available for all studies).

STK: serine–threonine kinases; mTOR: mammalian target of rapamycin; AKT: protein kinase B; PI3K: phosphatidylinositol 3-kinase; MAPK: mitogen-activated protein kinase; MEK: mitogen-activated protein kinase kinase; PFS: Progression-free survival; OS: overall survival.